Table 4 Participant Characteristics (Cognitive Interviews)
Characteristic | US | UK | Total Sample |
|---|---|---|---|
N | 15 | 5 | 20 |
Mean Age (years) | 64.7 (7.5) | 57.0 (7.8) | 62.8 (8.1) |
Gender (n, %) | |||
Female | 10 (66.7%) | 2 (40.0%) | 12 (60.0%) |
Male | 5 (33.3%) | 3 (60.0%) | 8 (40.0%) |
Ethnic/Racial Background (n, %) | |||
White | 11 (73.3%) | 4 (80.0%) | 15 (75.0%) |
Mixed | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Asian | 0 (0.0%) | 1 (20.0%) | 1 (5.0%) |
Black | 1 (6.7%) | 0 (0.0%) | 1 (5.0%) |
Othera | 3 (20.0%) | 0 (0.0%) | 3 (15.0%) |
Marital Status (n, %) | |||
Single | 1 (6.7%) | 2 (40.0%) | 3 (15.0%) |
Married/Living with partner | 12 (80.0%) | 2 (40.0%) | 14 (70.0%) |
Otherb | 2 (13.3) | 1 (20.0%) | 3 (15.0%) |
Employment Status (n, %) | |||
Full-time work | 2 (13.3%) | 2 (40.0%) | 4 (20.0%) |
Part-time work | 4 (26.7%) | 1 (20.0%) | 5 (25.0%) |
Otherc | 9 (60.0%) | 2 (40.0%) | 11 (55.0%) |
Education Level (n, %) | |||
University degree | 7 (46.7%) | 2 (40.0%) | 9 (45.0%) |
No University degree | 8 (53.3%) | 3 (60.0%) | 11 (55.0%) |
Interview Conducted | |||
In-Person (n) | 0 (0.0%) | 3 (60.0%) | 3 (15.0%) |
Telephone (n) | 15 (100.0%) | 2 (40.0%) | 17 (85.0%) |
Current Medication | |||
GLP-1 | 15 (100.0%) | 5 (100.0%) | 20 (100.0%) |
Insulin | 2 (13.3%) | 0 (0.0%) | 2 (10.0%) |
Pramlintide | 1 (6.7%) | 0 (0.0%) | 1 (5.0%) |
Current GLP-1 | |||
Exenatide extended release (either pen or tray) | 7 (46.7) | 0 (0.0%) | 7 (35.0%) |
Liraglutide | 4 (26.7) | 2 (40.0%) | 6 (30.0%) |
Dulaglutide | 3 (20.0%) | 0 (0.0%) | 3 (15.0%) |
Lixisenatide | 0 (0.0%) | 2 (40.0%) | 2 (10.0%) |
Exenatide twice daily | 0 (0.0%) | 1 (20.0%) | 1 (5.0%) |
Albiglutide | 1 (6.7%) | 0 (0.0%) | 1 (5.0%) |
Pramlintide | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |